Price
No data yet.
Social Signal Score
Analyst Ratings
15 analystsRevenue
$53.01M+56262.84%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Michael Ryan Gorenstein
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 610
- Beta
- 1.28
- Country
- CA
- Piotroski score
- 5 / 9 (Middling)
- Altman Z-score
- 13.22
Financials
Revenue
$53.01M+56262.8%Net Income
$32.09MEBITDA
$10.98MFree Cash Flow
$17.05MEPS (diluted)
$0.08Shares Outstanding (diluted)
385.31M+501.4%Operating Expenses
$20.36MCash & Debt
$797.02MReturn of Capital
$16.36MRevenue by Segment (annual)
$146.59MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $149.15M | $-9.61M | $-0.03 |
| 2024 | $117.61M | $41.08M | $0.11 |
| 2023 | $87.24M | $-73.96M | $-0.19 |
| 2022 | $86.75M | $-168.73M | $-0.45 |
| 2021 | $64.56M | $-396.11M | $-1.07 |
| 2020 | $46.72M | $-73.14M | $-0.21 |
| 2019 | $17.84M | $1.19B | $3.76 |
| 2018 | $12.12M | $-21.64M | $-0.15 |
| 2017 | $4.14M | $2.53M | $0.02 |
| 2016 | $412.3K | $-1.20M | $-0.02 |
| 2015 | $3.40M | $278.3K | $0.01 |
| 2014 | $-665.0K | $-4.15M | $-0.15 |
| 2013 | $-213.4K | $-26.9K | $-0.05 |
| 2012 | $0.00 | $-31.2K | $-0.07 |
Valuation
CRONhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
160+220.00%Social Signal Score
Mentions (7)
- Newsmarketbeat.com·11d ago·Positive
Cronos Group Investor Day Highlights Cannabis Growth, Cash Flow and Global Ambitions Cronos Group NASDAQ: CRON used its first Investor Day to outline its cultivation, genetics, brand and financial strategy, emphasizing its purpose-built greenhouse partnership with Mucci Farms, continued international expansion and a focus on cash flow generation.
View source ↗ - Newsglobenewswire.com·12d ago·Neutral
Cronos Hosts 2026 Investor Day TORONTO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is hosting its first Investor Day today, September 24, 2026, at its Cronos Growing Company Inc. Kingsville location.
View source ↗ - Newsseekingalpha.com·20d ago·Positive
Cronos: Invest In Cannabis With 50% Net Cash And GAAP Profitability Cronos Group Inc. is upgraded to a Buy, driven by a best-in-class balance sheet and improved profitability. CRON boasts $827 million in cash, no debt, and strong international expansion, with adjusted gross margins reaching 46%. Profitability is supported by disciplined cost management and positive GAAP operating profit, distinguishing CRON from Canadian peers.
View source ↗ - Newsglobenewswire.com·20d ago·Neutral
Cronos to Host 2026 Investor Day at its Cronos GrowCo Facility in Kingsville, Ontario Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026 Registration is now open for Cronos' first Investor Day, which will be hosted by the Cronos Leadership Team, on September 24, 2026
View source ↗ - Newszacks.com·33d ago·Negative
Are Medical Stocks Lagging Cronos Group (CRON) This Year? Here is how Cronos Group (CRON) and Curaleaf Holdings, Inc. (CURLF) have performed compared to their sector so far this year.
View source ↗ - Newsglobenewswire.com·34d ago·Neutral
Cronos' brand Spinach® Expands its Best-Selling Lineups of Edibles and Vapes TORONTO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos”), an innovative global cannabis company, is expanding its lineup of edible multipacks with the SOURZ by Spinach® Blue Raspberry Lemonade Fully Blasted multipack, featuring its first live resin gummy. This month the brand will also launch new flavors in its best-selling lineup of vape cartridges, Strawberry Banana and Sweet…
View source ↗ - Newszacks.com·48d ago·Neutral
Surging Earnings Estimates Signal Upside for Cronos (CRON) Stock Cronos Group (CRON) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
View source ↗
Earnings
Thu, Nov 5(in 4 weeks)
Consensus estimate $0.03 per share
Typical surprise +174.8% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$0.09 vs $0.01beat
- Mon, May 11$0.04 vs $0.01beat
- Thu, Feb 26$-0.00 vs $0.01miss
- Thu, Nov 6$0.07 vs $0.02beat
- Thu, Aug 7$-0.10 vs $-0.02miss
- Thu, May 8$0.02 vs $0.01beat
Estimates and results for CRON via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CRON officers and directors.
No open-market trades in the recent filings. All 100 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
100 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- John Yarmuthhouse · KY03 · disclosed Feb 19, 2021 (7d later)Buy$1,001 - $15,000
- John Yarmuthhouse · KY03 · disclosed Nov 15, 2020 (10d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.